Soon we’ll be able to diagnose Alzheimer’s with a blood test.
The test measures the levels of amyloidal peptide both in free form, connected to proteins or even tied to blood cells.
Researchers at Spain’s Araclon claim that the presence of amyloids in the blood is directly proportional to the possibility to develop the disease.
The article was published in the Journal of Alzheimer’s Disease.
Araclon had developed and patented the ABtest Kit, which can find 40 – 42 amyloid-beta in the blood.
Researchers are currently studying more than 400 people in the effort to obtain the data necessary to validate the ABtest Kit as an instrument to diagnose Alzheimer’s.
Conductors of the test claim that it “can distinguish between healthy subjects and those with cognitive deficits that prelude Alzheimer’s”.